Aim: To verify the efficacy of Citicoline, taken orally, in the prevention of neurological damage in patients with Chronic Open Angle Glaucoma (COA G). Methods: 30 subjects with COA G were divided into 2 groups: 18 subjects (CT group) were treated with Citicoline and 12 (PP group) were treated with placebo. Both groups underwent 3 cycles of treatment. A cycle lasted 60 days and after every cycle there was a wash-out period of 30 days. On day 0, 60, 90, 150, 180, 240 and 270 all subjects underwent an examination of the optic nerve fibres by GDx VVC and a simultaneous recording of pattern reversal VEP s and pattern ER G. Results: In both groups endocular pressure values kept steady below 21 mmHg. In the CT group the VEP s average amplitude regularly increased at the end of every cycle and moderately decreased at the end of the wash-out period. Retinocortical Time (RCT ) appeared significantly reduced at the end of every cycle in the CT group. VEP s average amplitude and RCT remained unchanged in the PP group. A slowing down of the TSNIT average, statistically non significant, appeared only at the end of the third cycle in the CT group. Conclusion: Citicoline administered orally at a dose of 500 mg, seems to have a neuroprotective effect. This effect is apparent after a cycle of at least 60 days and tends to moderately decrease at discontinuation of the drug.

Morreale Bubella, R., Carità, S., Badalamenti, R., Morreale Bubella, D. (2011). Neuroprotezione del paziente con glaucoma cronico ad angolo aperto:ruolo della Citicolina in soluzione orale. OTTICA FISIOPATOLOGICA, XVI(3), 171-177.

Neuroprotezione del paziente con glaucoma cronico ad angolo aperto:ruolo della Citicolina in soluzione orale

MORREALE BUBELLA, Raffaella;MORREALE BUBELLA, Daniele
2011-01-01

Abstract

Aim: To verify the efficacy of Citicoline, taken orally, in the prevention of neurological damage in patients with Chronic Open Angle Glaucoma (COA G). Methods: 30 subjects with COA G were divided into 2 groups: 18 subjects (CT group) were treated with Citicoline and 12 (PP group) were treated with placebo. Both groups underwent 3 cycles of treatment. A cycle lasted 60 days and after every cycle there was a wash-out period of 30 days. On day 0, 60, 90, 150, 180, 240 and 270 all subjects underwent an examination of the optic nerve fibres by GDx VVC and a simultaneous recording of pattern reversal VEP s and pattern ER G. Results: In both groups endocular pressure values kept steady below 21 mmHg. In the CT group the VEP s average amplitude regularly increased at the end of every cycle and moderately decreased at the end of the wash-out period. Retinocortical Time (RCT ) appeared significantly reduced at the end of every cycle in the CT group. VEP s average amplitude and RCT remained unchanged in the PP group. A slowing down of the TSNIT average, statistically non significant, appeared only at the end of the third cycle in the CT group. Conclusion: Citicoline administered orally at a dose of 500 mg, seems to have a neuroprotective effect. This effect is apparent after a cycle of at least 60 days and tends to moderately decrease at discontinuation of the drug.
Settore MED/30 - Malattie Apparato Visivo
Morreale Bubella, R., Carità, S., Badalamenti, R., Morreale Bubella, D. (2011). Neuroprotezione del paziente con glaucoma cronico ad angolo aperto:ruolo della Citicolina in soluzione orale. OTTICA FISIOPATOLOGICA, XVI(3), 171-177.
File in questo prodotto:
File Dimensione Formato  
ArtScient_Neuroprotezione del paziente con glaucoma cronico ad an golo aperto_OFsettembre2011.pdf

accesso aperto

Descrizione: Articolo principale
Dimensione 172 kB
Formato Adobe PDF
172 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/60519
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact